Lilly Asia Ventures co-led a $61.4m round for the antibody drug developer that will fund development of breast and gastric cancer drug candidates.
NovoCodex Biopharmaceuticals, a China-based antibody drug development subsidiary of pharmaceutical firm Zhejiang Medicine, has raised RMB400m ($61.4m) in series A funding, DealStreetAsia has reported.
Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly, co-led the round with venture capital firm Matrix Partners China.
The round was also backed by Hangzhou Sanhua Hongdao Investment and CMG-SDIC Capital, an investment fund jointly launched by State Development and Investment Corp and China Merchants Capital, a subsidiary of state-owned holding group…
